
Gracell Biotechnologies GRCL
Quarterly report 2022-Q2
added 08-15-2022
Gracell Biotechnologies Total Non Current Liabilities 2011-2026 | GRCL
Annual Total Non Current Liabilities Gracell Biotechnologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 51.9 M | 139 M | 139 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 139 M | 51.9 M | 110 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
802 M | $ 9.33 | 1.41 % | $ 603 M | ||
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
2.21 M | $ 0.87 | -2.13 % | $ 6.4 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.38 | 0.81 % | $ 3.71 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Galapagos NV
GLPG
|
2.41 B | $ 28.15 | 1.04 % | $ 2.69 B | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Grifols, S.A.
GRFS
|
7.22 B | $ 8.22 | 3.92 % | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
149 M | $ 30.95 | -0.34 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
11.5 M | $ 8.43 | -0.12 % | $ 76.1 M | ||
|
InflaRx N.V.
IFRX
|
254 K | $ 1.97 | -0.51 % | $ 152 M | ||
|
Incyte Corporation
INCY
|
315 M | $ 98.55 | -0.55 % | $ 19.2 B | ||
|
InMed Pharmaceuticals
INM
|
338 K | $ 0.71 | 1.27 % | $ 1.74 M | ||
|
Innoviva
INVA
|
377 M | $ 22.97 | -0.35 % | $ 1.55 B | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 104.02 | 2.41 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Jaguar Health
JAGX
|
10.3 M | $ 7.34 | -6.79 % | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
KalVista Pharmaceuticals
KALV
|
5.05 M | $ 26.68 | 0.02 % | $ 1.44 B | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
105 M | $ 1.45 | -2.68 % | $ 235 M | ||
|
Kamada Ltd.
KMDA
|
7.06 M | $ 8.16 | 0.68 % | $ 260 M | ||
|
Krystal Biotech
KRYS
|
2.78 M | $ 260.24 | 0.11 % | $ 7.53 B | ||
|
Kazia Therapeutics Limited
KZIA
|
11.6 M | $ 13.58 | 9.34 % | $ 1.8 B | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 220.06 | -2.13 % | $ 4.02 B | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.94 | -1.67 % | $ 4.84 M | ||
|
Liquidia Corporation
LQDA
|
10.3 M | $ 38.41 | 0.67 % | $ 3.31 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.08 | 0.62 % | $ 436 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.15 | 3.49 % | $ 2.95 B |